Thursday, 04 February 2021 11:14

Internationally recognized nanomedicine expert Prof. Hélder A. Santos becomes Visiting Professor at our laboratory

         Prof. Hélder A. Santos Prof. Hélder A. Santos

With the global benefits of the new science of nanomedicine growing each year, the University of Tartu is determined to stay at the forefront of the international collaborative research in this area.

We are pleased to announce that outstanding researcher, educator, and raising star in nanomedicine, Prof. Hélder A. Santos, joins the Laboratory of Precision and Nanomedicine of University of Tartu as a Visiting Professor (effective February 1st, appointment for 2 years).

Prof Santos is a physical chemist specialized in electrochemistry, biological mimetic models and soft interfaces. His current work bridges engineering, pharmaceutical and medical research. His research focus is in the use of biodegradable and biocompatible nanoporous silicon nanomaterials, polymers, the application of microfluidics technology for nanoparticle production for controlled drug delivery, diagnosis and treatment of cancer, diabetes, and cardiovascular diseases, and further clinical translation of these nanotechnologies. Currently, is a Full Professor in Pharmaceutical Nanotechnology, Head of the Nanomedicines and Biomedical Engineering Group, and Director of the Doctoral Program in Drug Research at the Faculty of Pharmacy, at the University of Helsinki. He is also a Fellow Member of Helsinki Institute of Life Science (HiLIFE), the Director of the FinPharmaNet (The Network of Drug Research Doctoral Programmes in Finland), Chair of Controlled Release Society Focus Group in Nanomedicine and Nanoscale Delivery, and Chairman and co-founder of Capsamedix Oy.

The involvement of Prof. Santos will further strengthen the collaborative ties between the research labs and institutions to further facilitate collaborative efforts in translational nanomedicine and training of next generation of nanomedicine experts.


Contact info: This email address is being protected from spambots. You need JavaScript enabled to view it.